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Background: Neuromyelitis optica spectrum disorder (NMOSD) is an auto-immune disease of the central nervous
system (CNS) associated with the IgG-antibody against aquaporin-4 (AQP4-IgG). There is little published
epidemiology of NMOSD from sub-Saharan Africa (SSA).
Methods: We retrospectively collated NMOSD cases admitted to our tertiary regional neurology centre.
Results: We identified 11 cases (10 female, average age 30 years). 64% (7/11) were seropositive for AQP4-IgG,
measured using indirect immunofluorescence. The remaining cases could either not afford tests, or had patho
gnomonic radiological features. 57% (4/7) of seropositive cases had concurrent/recent CNS infection. All pa
tients were treated with high-dose intravenous methylprednisolone (IVMP), and 36% (4/11) also had plasma
exchange. Only 55% (6/11) of the patients were seen by a neurologist at presentation: they had less relapses (1.3
vs 2.4), less diagnostic delay (2.3 vs 7.4 months), and were less disabled at the end of our review period. 10 cases
were immunosuppressed long-term: 60% on mycophenolate, 30% azathioprine, and one on rituximab.
Conclusion: Our study is the largest case series of NMOSD from the East Africa region. Patients faced challenges of
access to appropriate and affordable testing, and timely availability of a neurologist at onset, which had impacts
on their functional outcomes. The majority of the seropositive cases had recent/concurrent CNS infections,
suggesting triggered auto-immunity.

1. Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune relapsing central nervous system disorder (CNS), diagnosed
based on the presence of core clinical characteristic presentations, the
presence of aquaporin-4 immunoglobulin G antibodies (AQP4-IgG),
and/or pathognomonic findings on CNS magnetic resonance imaging
(MRI) as per the International Panel for NMOSD Diagnosis (IPND)
criteria [1]. It is strongly recommended that AQP4-IgG is tested using a
cell-based assay, but if negative or not available then the clinical char
acteristics and MRI findings can fulfil the NMOSD diagnostic criteria.
About one-third of AQP4-IgG seronegative NMOSD patients have been
found to be positive for antibodies against myelin oligodendrocyte

glycoprotein (MOG-Ab) [2]. Anti-MOG disease is another CNS autoimmune demyelinating syndrome which mimics the clinical presenta
tion of NMOSD but has been recently identified as a separate entity [3].
It has therefore been proposed that it is reasonable to test for both AQP4IgG and MOG-Abs in patients with an NMOSD presentation [4].
Patients presenting acutely with NMOSD should be promptly rec
ognised, investigated and then commenced on relapse treatment fol
lowed by long-term maintenance immunosuppression to prevent
devastating relapses [5]. However, there is variable availability of
testing for AQP4-IgG and MOG-Ab globally with the least accessibility
noted in low/lower-middle income countries in Africa [6], and coupled
with the lack of MRI scanners in Africa [7] this makes the diagnosis of
NMOSD and anti-MOG disease particularly more challenging in these

Abbreviations: CNS, Central nervous system; CSF, Cerebrospinal fluid; EDSS, Extended Disability Status Scale; HIV, Human immunodeficiency virus; HSV-2,
Herpes simplex virus type 2; ICD-10, nternational Classification of Diseases version 10; IPND, International Panel for NMOSD Diagnosis; IVMP, Intravenous
methylprednisolone; LETM, Longitudinally extensive tranverse myelitis; MMF, Mycophenolate mofetil; MOG, Myelin oligodendrocyte glycoprotein; MRI, Magnetic
resonance imaging; nd, not done; NMOSD, Neuromyelitis optica spectrum disorder; OCBs, Oligoclonal bands; ON, Bilateral simultaneous or sequential optic neuritis;
PLEX, Plasma exchange; RRMS, Relapsing-remitting multiple sclerosis; RTX, Rituximab; TPHA, Treponema pallidum haemagglutination assay.
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settings.
The epidemiology of NMOSD in developing countries is being
increasingly understood e.g. in Latin America, NMOSD prevalence var
ies from 0.37–4.2/100,000 inhabitants, with AQP4-IgG seropositivity
being 33–73.5% [8]. However, there remains a significant gap of data
from Africa e.g. in a 2013 systematic review of 216 population-based
studies, five reported the incidence and prevalence of NMOSD but
none were from Africa [9], and a 2018 review also revealed no preva
lence studies from Africa [10]. Latitude does not seem to be related to
NMOSD prevalence [11], yet to date there are less than 500 cases of
NMOSD published from Africa [12], of which the majority are from
North [13–15] and West [16–19] Africa, with a smaller cohort from
South Africa [20] and only one case report from East Africa [21].
Based on studies published from large multi-ethnic cohorts mostly in
developed countries, it has been consistently shown that NMOSD,
particularly atypical optic neuritis, is much more common [22], more
severe, and more likely to be associated with AQP4-IgG seropositivity in
patients of African and Afro-Caribbean background [8,23,24]. In a
retrospective analysis from eleven Brazilian hospitals, 81/153 cases of
NMOSD had at least one black grandparent, and they were more likely to
have worse disability at diagnosis when compared to Caucasian patients
[25]. We have previously reported the largest cohort of multiple scle
rosis (MS) from East Africa [26] from our ongoing registry project. Given
all the literature reviewed above, we report here NMOSD cases from our
hospital cohort as the local population seem to be more at risk of
developing severe disease.

diagnosis other than NMOSD. In addition, as per the MS research pro
tocol, we gathered information according to the ‘Treatment/Manage
ment’ and ‘Outcome’ sections of the MS registry protocol, which
included management of acute relapses and choice of immunosuppres
sion, and outcome measured using the Extended Disability Status Scale
(EDSS).
2.4. Data analysis and management
Case summaries were collected in a Microsoft Word document. We
tabulated the findings in a Microsoft Excel sheet. Neither of these doc
uments contained any patient identifiers, and both were passwordprotected and were stored in a shared drive within our institution’s
intranet, which is only accessible by the authors via passwords. The
information in these sheets could only be linked to the patient via a
handwritten sheet of random numbers that were locked in the office of
the leading author (DSS).
3. Results
We collected 11 cases, all of whom were of black African background
and indigenous to East Africa. The findings above are summarised in
Table 1. 91% (10/11) were female, with an average age of 30 years at
presentation (range 15–51 years). Longitudinally extensive tranverse
myelitis (LETM) and Optic neuritis (ON) – all bilateral simultaneous or
sequential – were the commonest first presentations in 45% (5/11) and
36% (4/11) of cases, and similarly for second presentations [27% (3/11)
and 18% (2/11) respectively]. One patient (case 1) had with both LETM
and ON at the first presentation i.e. classic Devic syndrome. 27% (3/11)
presented with acute brainstem syndrome (ABS), all as a first symptom
(including case 5; see Fig. 1 for respective MRI brain scan correlates),
and only one patient (case 6) had area postrema syndrome (APS) as a
second symptom after LETM (see Fig. 2 for MRI correlates). Two patients
(cases 5 and 7) had pathognomonic dystonic spasms (see Supplementary
Video 1 of case 5, Fig. 3).
In terms of AQP4-IgG testing, 64% (7/11) had a positive result from
serum, of which three cases also had a positive test in CSF (CSF AQP4IgG was not done in the remaining 4 patients who were seropositive).
Case 11 could not afford testing for AQP4-IgG, and the remaining pa
tients (cases 8 through 10) were seronegative, but we included these
cases in our series for the following reasons:

2. Materials and methods
2.1. Ethical considerations
Our protocol of our continuing MS cohort study at our regional ter
tiary referral hospital has been approved by our Institutional Ethics
Review Committee (approval number REC-99/2018). The protocol in
cludes looking for MS mimics and chameleons [27] particularly
NMOSD.
2.2. Informed consent and patient details
We have obtained written informed consent from all the patients for
whom we have supplied MRI images as well as the supplementary video,
and these consent forms have been filed in their medical records at our
hospital. The patient identifiers from the images and video have been
removed or obscured to maintain patient confidentiality.

- Our institution does not offer cell-based assay testing for AQP4-IgG;
- Case 9 and 11 both presented with bilateral sequential ON then
LETM;
- Case 8 presented with LETM and case 10 with bilateral simultaneous
ON extending over half the optic nerve length on MRI (see Fig. 4for
MRI of optic nerves in case 10) with an altitudinal visual field defect,
and both required PLEX.

2.3. Identification of NMOSD cases
We performed case-finding for NMOSD cases from our MS registry
through a combination of:
1. International Classification of Diseases version 10 (ICD-10) coding
for patients discharged from our hospital (our institution does not
code for outpatient visits) with the following codes: NMOSD, acute
transverse myelitis in demyelinating disease of CNS, optic neuritis,
acute brainstem syndrome, area postrema syndrome, diencephalitic
syndrome and narcolepsy;
2. Positive AQP4-IgG antibodies in serum and/or cerebrospinal fluid
(CSF) obtained from our laboratory database as per the ‘In
vestigations’ section of our MS registry data collection protocol;
3. Recollection from memory by the neurologists at our institution
(authors DSS, JH and PM).

There were other positive results from investigations that we noted,
most notably that the majority (4/7) of AQP4-IgG positive cases had
laboratory, including CSF, evidence of concurrent or recent CNS infec
tion: tuberculosis (TB, case 2), herpes simplex virus type 2 (HSV-2, case
6), syphilis (case 7: see Fig. 5for MRI of LETM), and sterile meningitis
with pleocytotic CSF [case 1, who also had oligoclonal bands (OCBs) in
CSF]. Case 8 had lymphocytic CSF but no positive microbiology or PCR/
serology.
10 of the 11 patients were treated with high-dose intravenous
methylprednisolone (IVMP), administered as 1 gram per day for three to
five days, for each acute relapse, and some were given a tapering dose of
oral prednisolone of variable doses and duration after IVMP. All the
cases with concurrent/recent infections were treated with the appro
priate anti-microbials before embarking on IVMP treatment, as directed
by our infectious disease specialists: case 6 was given fourteen days of
intravenous acyclovir together with PLEX; case 2 was treated with anti-

We reviewed all cases and collected information on the clinical
presentation(s), including timelines, and investigation results, particu
larly MRI findings and AQP4-1gG results in order to match the IPND
criteria as well as to ensure there were no ‘red flags’ to suggest a
2
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Table 1
Summary of results of NMOSD cases.
Case
no.:
Age at onset (in years)
Core clinical
ON
characteristic
LETM
presentationa
APS
ABS
AQP4-IgG
Serum
antibody:
CSF
CSF (NR): white cell count
(<5/mm3)b
glucose (2.22–3.89 mmol/L)
protein (0.15–0.45 g/L)
positive microbiology
OCBs
PLEX after IVMP
Neurologist involved at onset
Delay to diagnosis (in months)
Relapses before diagnosis
Maintenance
immunosuppression
Relapses after
immunosuppression
EDSS at last review
Diagnosis to last review
(months)
Additional notes

AQP4-IgG antibody positive

AQP4-IgG antibody -ve/unavailable

1

2

3

4

5

6

7

8g

9

10

11

15
1
1

17
1
2

22

36

45

51

18

2

36
2
1

1

1

30
1

34
2

+ve
nd
32
(76%c)
3.32
1.59
n
-ve
n
y
0
1
None

+ve
ndd
nd

1
+ve
nd
<5

+ve
+ve
<5

1
+ve
naf
na

1
2

26
1
2

+ve
+ve
<5

-ve
-ve
<5

1
nd
nd
nd

3.39
0.23
n
-ve
n
y
7
2
MMF

3.11
0.37
n
-ve
n
y
1
1
MMF

na
na
na
nd
y
y
1
1
AZP

5.36
0.36
TPHA
-ve
n
n
5
2
MMF

-ve
-ve
61
(85%c)
3.6
0.57
n
-ve
y
n
3
2
RTX

-ve
-ve
<5

nd
nd
nd
nd
n
y
14
4
MMF

+ve
+ve
145
(90%c)
3.42
0.48
HSV2
-ve
y
n
1
1
MMF

2.31
0.44
n
-ve
n
n
7
3
MMF

3.55
0.17
n
-ve
y
y
0
1
AZP

nd
nd
nd
nd
n
n
12
2
AZP

None

nae

None

None

None

None

1

None

None

None

None

e

na
46

2
11

7
26

1
18

1
39

8
13

7
9

2
32

8
18

2
21

7
48

OCBs +ve
after 4
years

First
treated as
CNS TB

first
treated as
RRMS

Postpartum &
lactating

Tonic
spasms

Anti-MOG
negative

Could
not
afford
tests

Relapse as
noncompliant

Abbreviations: +ve = positive; -ve = negative; ABS = acute brainstem syndrome; APS = area postrema syndrome; AZP = azathioprine; CNS = central nervous system;
CSF = cerebrospinal fluid; EDSS = extended disability status scale; HSV-2 = Herpes simplex virus type 2; IVMP = intravenous methylprednisolone; LETM = longi
tudinally extensive tranverse myelitis; MMF = mycophenolate mofetil; MOG = myelin oligodendrocyte protein; na = not available; nd = not done; NR = normal range;
OCBs = oligoclonal bands; ON = bilateral simultaneous or sequential optic neuritis; PLEX = plasma exchange; PCR = polymerase chain reaction; RRMS = relapsingremitting multiple sclerosis; RTX = rituximab; TB = tuberculosis; TPHA = treponema pallidum haemagglutination assay
a
Number denotes presentation: “1” = first presentation, “2” = second presentation.
b
Red cell counts all <5mm3.
c
Percentage lymphocytes.
d
Not done as evidence of pulmonary tuberculosis so treated empirically for CNS disease.
e
Lost to follow-up as emigrated.
f
Not available as done in another country and records unavailable.
g
Male patient (remainder of cases all female).

Fig. 1. Coronal T2 (left image) and sagittal (right image) fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequences of case 5
showing a hyper-intense expansile lesion of the medulla and cervical-medullary junction, who presented with acute brainstem syndrome and quadriparesis.
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Fig. 2. (a) Axial and coronal MRI FLAIR sequences showing pontomedullary non-enhancing T2/FLAIR hyper-intense signals in case 6 which manifested as persistent
vomiting and vertigo in keeping with an area postrema syndrome. (b) The patient first presented with LETM (b) at another hospital (source images unavailable). This
MRI sagittal T2 slice of thoracic spine shows hyperintense spinal cord signals from C7-T9 (non-enhancing as post-PLEX).

Fig. 3. Axial spectral presaturation with inversion recovery (SPIR) MRI images of the orbits for case 10, who presented with bilateral simultaneous optic neuritis,
showing hyper-intense signal along most of the right optic nerve (left image) with bilateral optic nerve sheath enhancement (right image; more evident for left
optic nerve).

tubercular therapy and dexamethasone for two weeks then with IVMP;
case 7 was treated with penicillin G for 2 weeks before proceeding to
IVMP. 36% (4/11) had plasma exchange (PLEX) after IVMP if there was
no clinical response and/or MRI findings were suggestive of severe
disease.
Just over half (6/11) of the patients were seen by a neurologist
during the first presentation, and when compared to the remaining five
cases, they had: (i) less relapse presentations before the diagnosis was
made (average 1.3 vs 2.4 relapses); (ii) less delay to NMOSD diagnosis
(average 2.3 months vs 7.4 months); and (iii) less disability when
assessed at the end of our review period (average EDSS score of 3.6 vs
5.4).
All our NMOSD patients were commenced on long-term immuno
suppression, although we did not have details for case 1 as she trans
ferred her care to outside our facility during her acute illness and was
lost to follow-up. For the remaining cases, the most frequently pre
scribed regimen was mycophenolate in 60% (6/10) of cases, with
azathioprine (3/10) and rituximab (case 8 alone) being used in the
remainder of the cohort. Average follow-up time was 25 months (range
9 to 48), with no difference if first seen by a neurologist.

Although case 3 was diagnosed with NMOSD at 7 months by one of
the authors, appropriate immunosuppressive therapy was not
commenced until 3 years later as the patient was lost to follow-up and
sought treatment at various locations outside our institution and was
managed as relapsing-remitting MS; during this time she had 3 further
relapses with a relatively poor EDSS when she returned to our services.
Case 4 was 3 months post-partum when she developed LETM, and was
breastfeeding so she made an informed decision with her neurologist not
to commence on immunosuppression after the positive serum AQP4-IgG
result came out given the perceived risks. Unfortunately she relapsed
with bilateral simultaneous ON, although with good recovery, within
the same month at which point she decided to commence
immunosuppression.
4. Discussion
4.1. Demographics
The NMOSD cohort at our institution was predominantly female with
an average of 30 years, which is in keeping with what has been found in
4
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Fig. 4. Sagittal T2 with fat suppression (left image) and T1 with contrast (right image) MRI sequences of case 11 who presented with quadriparesis secondary to
longitudinally extensive tranverse myelitis.

the absence of available and appropriate serology testing has been used
in other African cohorts to justify immunosuppression e.g. 15.9% of the
Algeria cases who did not fulfil the NMOSD criteria were put immuno
suppression as they were deemed “high risk”.
MOG-Ab was not available at the time case 8 was last followed up,
but was available for case 10 and it was negative, which again lends
some support to NMOSD diagnosis. This lack of availability of diagnostic
tests for NMOSD was shown in a recent survey, where Africa had the
least accessibility to either AQP4-IgG or MOG-Ab testing [6]. The survey
did not differentiate between the type of assay; whilst our institution
does not have access to cell-based assays for AQP4-IgG, there is evidence
that in some parts of Africa e.g. Egypt such assays are readily available
[15]. This variable access to high-quality testing raises the question as to
whether there needs to be an international effort to expand NMOSD
diagnostics and make them more affordable, or whether to adjust the
diagnostic criteria to cater for this chronic laboratory insufficiency in
poorer countries. As a result of this study, we are in the process of
identifying a laboratory that does provide cell-based assays for identi
fying AQP4-IgG antibodies, and will then recall the patients for
retesting.

Fig. 5. Still of supplementary video 1 of case 5 demonstrating dystonic spasms
pathognomonic of NMOSD.

other studies from Africa [13–17]. Similarly, ON and LETM were the
most frequently reported symptoms at relapse presentation, with LETM
being the most frequent overall (73%, and the Algerian cohort was 75%
[17]), but the concomitant optico-spinal involvement i.e. classic Devic
syndrome seemed to more prevalent in Morocco [13] and Senegal [16].

4.3. Impact of early neurologist review
One of our most important findings is the significant impact early
involvement of a neurologist made to the timeline to diagnosis (average
of 2.3 months from first presentation if seen by a neurologist first),
number of relapses before diagnosis (1.3 vs 2.4 average relapses), and
outcome of the patients as measured by EDSS (3.6 vs 5.4). Despite being
the economic hub of the East Africa region, Kenya has only 18 neurol
ogists for a population of 47 million, a neurology service gap that has
been shown to be consistent across Africa [31]. The majority are based
in the capital centre in institutions such as our regional referral hospital,
which partly explains why 5/11 of our NMOSD cases did not see a
neurologist at first presentation and led to the delayed diagnosis (7.4
months delay on average): three of these patients first presented with
LETM but could not access a neurologist due to the towns they were
living in (cases 6 and 7). Case 8 was seen by a neurosurgeon first because
the MRI scan suggested a spinal cord tumour. One of the five patients
(case 9) first presented with bilateral sequential ON but was managed on
both occasions by an ophthalmologist who did not refer the patient
forward, and then she had a devastating LETM relapse which led to her
presentation to our hospital, from which she remained wheelchairbound. Case 11 was admitted to the national public referral hospital

4.2. AQP4-IgG testing and status
AQP4-IgG seropositivity in our cohort was 64% (7/11), which is
comparable to the range of 38% [17] to 62.5% [16] from African co
horts, although altogether much less when compared to 73–90% in in
ternational cohorts [28]. Two of the four seronegative patients (cases 9
and 11) fulfilled the clinical and radiological criteria for NMOSD diag
nosis. The two remaining cases each had only one core clinical charac
teristic, but we included them in our cohort because: (i) both had
NMOSD-concordant MRI findings; (ii) red flags for other differentials
had been ruled out in the diagnostic workup; (iii) our laboratory only
offers indirect immunofluorescence for detection of AQP4-IgG, which is
known to be much less sensitive [29] than the cell-based assays rec
ommended by the IPND (1); and (iv) both patients had monophasic
illnesses, which are more likely to be seronegative when compared to
those with established relapsing NMOSD [30]. Such risk stratification in
5
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but was admitted under a physician first before being sent to the
neurologist. Her diagnosis was made on clinical grounds after the second
relapse with ON as she could not afford any investigations. Delays in
diagnosis, which lead to delay in treatment, has been shown to be a
significant factor contributing to long-term disability in NMOSD with a
history of LETM [32], which explains why these patients in our cohort
had a poorer outcome. Aside from increasing the neurology healthcare
workforce in developing countries, simple measures such as stand
ardised protocols for managing atypical ON and/or LETM have been
shown to improve diagnoses rates, timely treatment, and overall out
comes in resource-poor settings for NMOSD patients [33], therefore
national or regional guidelines for demyelinating diseases can mitigate
some of the healthcare shortfalls highlighted by our cohort.
Case 3 was first seen by a neurologist but had the worst EDSS score of
7 when compared to the other five cases (average EDSS score 1.5) who
were also seen by a neurologist at first presentation. This was because of
a combinations of factors. Firstly, they were lost to follow-up after the
second relapse which is when the AQP4-IgG was requested; the turnaround time for results from our referral laboratory is three weeks on
average. The results came back positive but were not flagged up by our
laboratory as AQP4-IgG does not feature as a critical result that requires
verbal reporting to the attending clinician. We have logged this as a
clinical incident and as a result our laboratory now has a protocol to
have all positive AQP4-IgG results immediately telephoned to the
neurologist in charge. Secondly, the patient self-referred to another
neurologist outside our institution for a second opinion, and who was
therefore not privy to her laboratory findings from the first two pre
sentations. She was thus treated as a case of relapsing-remitting MS – a
misdiagnosis that can happen in up to 40% of patients [24,30] – which
may have contributed to her ongoing deterioration since it is now well
established that disease-modifying drugs used in MS exacerbate NMOSD
[34].

availability. In other African cohorts, cyclophosphamide is used more
often [14,15], which we tend to avoid given the implications to fertility
in a female-predominant disease. Rituximab is generally expensive and
not easily available, and was only used in the management of case 8 as
they did not like to daily tablets; it is used more frequently for NMOSD in
other parts of Africa especially Egypt [15]. Only one patient (case 7) had
a relapse due to non-compliance with the oral steroids and
mycophenolate.
5. Conclusions
We have described the largest indigenous case series of NMOSD from
the East Africa region. The demography in terms of gender and age were
similar to other NMOSD cohorts reported internationally, but there were
also some unique differences within our cases, mainly that majority of
the sero-positive patients had other CNS infections, suggesting parainfectious pathogenesis. Documenting the patient journey from symp
tom onset to outcomes elucidated specific challenges: variable access to
appropriate and affordable diagnostic testing, especially for cell-based
assays to detect AQP4-IgG, and suboptimal availability of, and referral
to, a neurologist at onset of the disease which is a very modifiable risk
factor. Delayed and incorrect diagnoses negatively impacted on patient
outcomes in terms of disability, which has implications on how
neurology-specific healthcare infrastructure should be aligned and
developed in order to improve the management of conditions such as
NMOSD in relatively resource-poor settings.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ensci.2021.100320.
Data statement
The clinical information and imaging data used to support the
findings of this study are included within the article. According to our
institutional information governance regulations, the anonymised data
can be requested from the corresponding author.

4.4. Concurrent CNS infections
It has been postulated that infections may be a trigger to the autoimmunity in NMOSD [35], and interestingly over half of AQP4-IgG
seropositive patients in our cohort had a recent on concurrent infec
tion, each of which have been reported to be associated with NMOSD
onset: CNS tuberculosis in case 2 [36], HSV-2 in case 6 [37], and neu
rosyphilis in case 7 [35–38]. Case 1 had a sterile meningitis with no
isolate; repeat CSF was only done 4 years later which was normal. Case 2
did not have CSF examination at presentation due to presence of pul
monary tuberculosis, and they were then lost to follow-up in the same
year. Case 1 and 6 had lymphocytic CSF, and they declined follow-up
CSF studies after their acute infections were treated. Case 8 had a lym
phocytic CSF but negative microbiology and serology studies that
excluded concurrent infection; treatment for NMOSD led to good
outcome long-term and the attending clinician therefore decided against
repeat CSF.
All acute neurology admissions at our institution are tested for
infection by human immunodeficiency virus (HIV) as per a previously
published protocol [39], but none of the NMOSD patients had concur
rent HIV infection. There is some evidence from the South African cohort
that post-infectious auto-immunity plays a role in NMOSD pathogenesis
in HIV-infected patients, who tend to have more tumefactive CNS lesions
[20].
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E. Aka-Anghui, B. Assi, Devic’s optica neuromyelitis (NMOSD) in ivory coast: a
second confirmed case report, Afr. J. Neurol. Sci. 38 (1) (2019).
[20] A.I. Bhigjee, A.A. Moodley, I. Roos, C.L. Wells, P. Ramdial, M. Esser, The
neuromyelitis optica presentation and the aquaporin-4 antibody in HIVseropositive and seronegative patients in KwaZulu-Natal, South Africa, South Afr.
J. HIV Med. 18 (1) (2017) 684.
[21] M. Kaddumukasa, A. Musubire, M. Kaddumukasa, S. Matovu, E. Katabira,
Neuromyelitis optica in a Ugandan woman: a case report, J. Med. Case Rep. 7
(2013) 177.
[22] E.P. Flanagan, P. Cabre, B.G. Weinshenker, J.S. Sauver, D.J. Jacobson, M. Majed, et
al., Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica
spectrum, Ann. Neurol. 79 (5) (2016) 775–783.

7

